A Potential Role of Plant/Macrofungi/Algae-Derived Non-Starch Polysaccharide in Colitis Curing: Review of Possible Mechanisms of Action

Abstract

Multiple in vitro and in vivo model investigations have suggested a broad spectrum of potential mechanisms by which plant/macrofungi-derived non-starch polysaccharides may play a role in the treatment of inflammatory bowel disease (IBD). This article reviews the in vivo and in vitro evidence of different plant-derived polysaccharides for IBD therapy. Their underlying mechanisms, particularly the molecular mechanisms associated with protective effects in the treatment and prevention of IDB, have been well summarized, including anti-inflammatory, epithelial barrier repair, and the regulation of intestinal flora. Emerging studies have observed the potent role of probiotics in IBD, particularly its ability to modulate gut microbiota, a well-known key factor for IBD. In summary, plant/macrofungi-derived polysaccharides have the potential to be a promising agent for the adjuvant treatment and prevention of IBD and will contribute to the design of well-designed clinical intervention trials that will ultimately improve the therapy of IBD.

Dioscoreae persimilis polysaccharide ameliorates DSS-induced ulcerative colitis in mice through modulation of microbiota composition

“…An increasing number of studies have shown that polysaccharides have wide range of pharmacological effects, especially the protective effects on gastrointestinal ora [22][23][24][25]. Polysaccharides extracted from the sporoderm-broken spores of Ganoderma lucidum (BSGLP) show suppression effects of obesity and in ammation through modulating in ammation, gut microbiota, and gut barrier function [26].…”